Stelara faces potential biosimilar competition due to its secondary patents, which are being challenged by biosimilar manufacturers. These challenges aim to clear the way for earlier market entry of generic versions of the drug.
How are Stelara's secondary patents being contested?
Biosimilar companies are challenging several of Stelara's secondary patents through legal means, including inter partes review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO). These challenges argue that the challenged patents are invalid. For instance, Amgen has been involved in challenging patents related to Stelara's use in treating certain inflammatory conditions.
When might biosimilars of Stelara become available?
The availability of Stelara biosimilars is contingent on the outcomes of patent litigation and regulatory approvals. While the primary patent protecting Stelara was set to expire in 2023, secondary patents have extended its market exclusivity. If the challenges to these secondary patents are successful, biosimilar entry could occur sooner than anticipated. For example, early 2024 has been discussed as a potential timeline for some biosimilar launches, though this remains subject to legal and regulatory developments. DrugPatentWatch.com tracks these patent expirations and challenges, providing detailed timelines.
What is the impact of these patent challenges on Stelara's market exclusivity?
The success of biosimilar companies in invalidating Stelara's secondary patents would significantly reduce the drug's remaining market exclusivity. This could lead to a sooner introduction of more affordable biosimilar alternatives, impacting the market share and revenue of the originator drug.
What are the key secondary patents for Stelara that are under scrutiny?
Stelara, marketed by Janssen (a subsidiary of Johnson & Johnson), has several secondary patents that extend beyond its initial composition of matter patent. These often relate to methods of use, formulations, or manufacturing processes. The specific patents being challenged vary, but they are crucial for maintaining the drug's exclusivity. Information on these patents and their expiration dates can be found through resources like DrugPatentWatch.com.
How do biosimilar manufacturers prepare for Stelara's market entry?
Biosimilar manufacturers undertake extensive development and regulatory processes to gain approval for their products. This includes demonstrating biosimilarity to Stelara through analytical studies, clinical trials (if necessary), and ensuring consistent manufacturing quality. Concurrently, they often engage in patent litigation to preemptively address or invalidate existing patents that could block their entry.
What is Stelara used to treat?
Stelara (ustekinumab) is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Its effectiveness in these inflammatory conditions is a significant factor in its commercial success and the interest in its biosimilar versions.
What is the difference between biosimilars and generics?
Generic drugs are exact copies of small-molecule drugs. Biosimilars, on the other hand, are highly similar versions of complex biologic medicines, with no clinically meaningful differences in terms of safety, purity, and potency. This distinction is due to the inherent complexity of manufacturing biologic drugs.
Who are the main competitors or companies involved in Stelara biosimilars?
Several pharmaceutical companies are developing or have expressed interest in developing Stelara biosimilars. Companies like Amgen, Samsung Bioepis, and Pfizer are among those actively involved in the biosimilar space for various therapeutic areas, including potentially for Stelara.
What are the economic implications of Stelara biosimilar entry?
The introduction of biosimilars typically leads to significant price reductions for biologic medications. For Stelara, biosimilar competition is expected to lower treatment costs for healthcare systems and patients, increasing access to these important therapies. This can result in substantial savings for payers and a shift in market dynamics.